Abstract
Endpoint surrogacy is an important concept in oncology trials. Using a surrogate endpoint like progression-free survival as the primary endpoint—instead of overall survival—would lead to a potential faster drug approval and therefore more cancer patients with an earlier opportunity to receive the newly approved drugs.
Original language | English |
---|---|
Pages (from-to) | 333-334 |
Number of pages | 2 |
Journal | British Journal of Cancer |
Volume | 123 |
Issue number | 3 |
DOIs | |
State | Published - Aug 4 2020 |